Zhenzhen Liu Selected Research

pertuzumab

2/2024	Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.
1/2023	Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012).
12/2022	Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment-a retrospective cohort study.
9/2022	Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen.
1/2021	Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial.
4/2011	Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhenzhen Liu Research Topics

Disease

64	Neoplasms (Cancer) 02/2024 - 08/2010
52	Breast Neoplasms (Breast Cancer) 05/2024 - 11/2012
35	Cataract (Cataracts) 04/2024 - 09/2007
14	Neoplasm Metastasis (Metastasis) 04/2024 - 03/2014
12	Inflammation (Inflammations) 06/2023 - 01/2014
10	Hepatocellular Carcinoma (Hepatoma) 12/2021 - 02/2016
9	Triple Negative Breast Neoplasms 10/2023 - 01/2019
6	Wounds and Injuries (Trauma) 03/2024 - 05/2015
6	Pre-Eclampsia (Preeclampsia) 12/2023 - 03/2012
6	Hypertension (High Blood Pressure) 07/2023 - 03/2012
5	Hypoxia (Hypoxemia) 04/2024 - 03/2016
5	Carcinogenesis 02/2024 - 08/2019
5	Pathologic Complete Response 01/2023 - 05/2014
5	Fibrosis (Cirrhosis) 03/2022 - 01/2019
5	Capsule Opacification 02/2022 - 01/2017
4	Liver Cirrhosis (Hepatic Cirrhosis) 02/2024 - 04/2014
4	Myopia 09/2023 - 04/2021
4	Lung Neoplasms (Lung Cancer) 07/2022 - 08/2017
4	Rectal Neoplasms (Rectal Cancer) 01/2022 - 01/2020
4	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 03/2016
4	Liver Neoplasms (Liver Cancer) 01/2022 - 02/2016
4	Non-alcoholic Fatty Liver Disease 01/2021 - 01/2014
4	Hemolysis 08/2020 - 06/2012
4	Infections 07/2020 - 04/2018
3	Heart Failure 05/2024 - 01/2023
3	Insulin Resistance 05/2024 - 01/2014
3	Myocardial Infarction 03/2024 - 03/2016
3	Glaucoma 12/2023 - 02/2023
3	Lymphatic Metastasis 10/2023 - 02/2010
3	Reperfusion Injury 10/2023 - 03/2016
3	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2019
3	Stomach Neoplasms (Stomach Cancer) 01/2022 - 08/2020
3	Hepatitis E 01/2021 - 10/2019
2	Coronary Disease (Coronary Heart Disease) 05/2024 - 04/2024
2	Cardiovascular Diseases (Cardiovascular Disease) 05/2024 - 10/2020
2	Acquired Immunodeficiency Syndrome (AIDS) 05/2024 - 07/2023
2	Cardiotoxicity 02/2024 - 12/2015
2	Iron Overload 02/2024 - 01/2022
2	Residual Neoplasm 01/2024 - 01/2023
2	Diabetic Nephropathies (Diabetic Nephropathy) 11/2023 - 01/2023
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2023 - 10/2015
2	Aphakia 02/2023 - 01/2022
2	Ischemia 01/2023 - 04/2014

Drug/Important Bio-Agent (IBA)

21	Proteins (Proteins, Gene)FDA Link 12/2022 - 09/2007
14	Biomarkers (Surrogate Marker)IBA 05/2024 - 01/2019
10	Hormones (Hormone)IBA 05/2024 - 03/2014
10	MicroRNAs (MicroRNA)IBA 03/2024 - 11/2012
9	Trastuzumab (Herceptin)FDA Link 02/2024 - 01/2020
9	Long Noncoding RNAIBA 04/2023 - 01/2019
8	Glucose (Dextrose)FDA LinkGeneric 05/2024 - 03/2016
8	human ERBB2 proteinIBA 05/2024 - 01/2019
7	Docetaxel (Taxotere)FDA Link 01/2023 - 12/2011
6	pertuzumabIBA 02/2024 - 04/2011
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2024 - 12/2019
5	pyrotinibIBA 10/2023 - 01/2022
5	Messenger RNA (mRNA)IBA 04/2023 - 03/2012
5	LipidsIBA 03/2023 - 12/2011
5	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 01/2021
5	Interleukin-10 (Interleukin 10)IBA 11/2020 - 02/2013
4	Epidermal Growth Factor (EGF)IBA 02/2024 - 01/2020
4	IronIBA 02/2024 - 08/2020
4	Epirubicin (Ellence)FDA LinkGeneric 10/2023 - 01/2021
4	RNA (Ribonucleic Acid)IBA 05/2023 - 01/2020
4	Estrogen ReceptorsIBA 12/2022 - 11/2012
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2022 - 04/2011
4	CytokinesIBA 11/2020 - 01/2015
4	Interleukin-27 (Interleukin 27)IBA 07/2015 - 04/2012
3	Triglycerides (Triacylglycerol)IBA 05/2024 - 01/2018
3	AnthracyclinesIBA 02/2024 - 01/2021
3	Silicone OilsIBA 01/2024 - 01/2021
3	Sirtuin 1IBA 12/2023 - 01/2022
3	Therapeutic UsesIBA 11/2023 - 02/2018
3	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2023 - 01/2021
3	Retinaldehyde (Retinal)IBA 01/2023 - 01/2014
3	CholesterolIBA 01/2023 - 04/2018
3	Progesterone Receptors (Progesterone Receptor)IBA 12/2022 - 11/2012
3	ErbB Receptors (EGF Receptor)IBA 01/2022 - 04/2011
3	VaccinesIBA 01/2021 - 07/2015
2	Mesalamine (Mesalazine)FDA LinkGeneric 04/2024 - 01/2021
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 03/2024 - 01/2018
2	BilirubinIBA 02/2024 - 01/2023
2	N-acetyltalosaminuronic acid (NAT)IBA 01/2024 - 01/2023
2	ProdrugsIBA 11/2023 - 01/2020
2	Lactic Acid (Lactate)FDA LinkGeneric 10/2023 - 01/2022
2	HydrogelsIBA 06/2023 - 04/2016
2	Histones (Histone)IBA 01/2023 - 01/2023
2	Untranslated RNA (Noncoding RNA)IBA 01/2023 - 01/2020

Therapy/Procedure

26	Neoadjuvant Therapy 04/2024 - 05/2014
26	Therapeutics 10/2023 - 04/2014
21	Intraocular Lenses (Intraocular Lens) 01/2024 - 03/2016
8	Phacoemulsification 01/2024 - 01/2021
8	Drug Therapy (Chemotherapy) 10/2023 - 05/2020
6	Immunotherapy 10/2023 - 01/2012
4	Intraocular Lens Implantation 12/2023 - 11/2016
4	Vitrectomy 02/2023 - 12/2021
4	Cataract Extraction 08/2022 - 11/2016
4	Slit Lamp 11/2019 - 11/2016
3	Lymph Node Excision (Lymph Node Dissection) 01/2024 - 04/2021
3	Adjuvant Chemotherapy 08/2022 - 02/2016
2	Length of Stay 01/2023 - 01/2022